Depression and inflammation in rheumatic diseases
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2016, Vol 70, Issue
Abstract
It is known that the prevalence of depression in rheumatologic patients is higher than in the general population. Socioeconomic factors are not a sufficient explanation of mood disorder in these patients. Symptoms reported by patients with chronic inflammatory diseases resemble changes defined as “sickness behavior”. Mood disorders among somatic patients could be explained by disturbances of the immune system according to the monoaminergic theory of depression. Inflammatory factors such as IL-1 (interleukin-1), IL-2 (interleukin-2), IL-6 (interleukin-6), TNF-α (tumor necrosis factor α), and IFN-γ (interferon-γ) act within the CNS (central nervous system). They get through from peripheral tissues as well as being synthesized de novo by neurons. This cytokine activity correlates positively with depression intensity as well as with genetic polymorphism of the serotonin (5-HT) transporter. The theory of glucocorticoid resistance-mediated depression (limbic-hypothalamic-pituitary-adrenal [LHPA] axis) is also connected with gained proinflammatory cytokines activity. It might assume the form of a vicious circle. Depressed mood is probably linked with depression in immune-mediated diseases. An elevated level of proinflammatory cytokines is able to activate IDO (indoleamine 2,3-dioxygenase) – an enzyme catabolizing tryptophan (5-HT precursor). Those reactions probably play the main role at the biochemical level. IDO metabolites extensively disturb neurotransmission. 3-Hydroxykynurenine (3OH-KYN), quinolinic acid (Quin) and kynurenic acid (KYNA) are neurotoxic by releasing oxidative stress mediators. Moreover, they activate MAO (monoamine oxidase), which degrades neurotransmitters responsible for stable mood. Bidirectional communication between the neuroendocrine and immune systems is significant for depression treatment, as well as CNS protection against incremental neurodegenerationamong seemingly diverse diseases.
Authors and Affiliations
Aleksandra Buras, Napoleon Waszkiewicz, Agata Szulc
Keywords
Related Articles
- EP ID EP220750
- DOI -
- Views 148
- Downloads 0
Znaczenie mutacji BRAF dla progresji i terapii czerniaka, raka brodawkowatego tarczycy i raka jelita grubego
Mutacje w BRAF bardzo często występują w wielu typach nowotworów, m.in. w czerniaku, raku brodawkowatym tarczycy i raku jelita grubego. BRAF jest elementem szlaku sygnałowego RAS/RAF/MEK/ERK (MAPK), którego ciągła aktywa...
Daratumumab – breakthrough drug in multiple myeloma therapy
Multiple myeloma (MM) remains incurable despite important recent advances in treatment. Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patien...
Cannabinoids – a new weapon against cancer?
Cannabis has been cultivated by man since Neolithic times. It was used, among others for fiber and rope production, recreational purposes and as an excellent therapeutic agent. The isolation and characterization of the s...
Zastosowanie wysokich dawek tokoferolu w prewencji i potencjalizacji działania dioksyn w doświadczalnym zapaleniu
Emisja do środowiska toksycznych i stabilnych substancji chloroorganicznych, z których jedną z ważniejszych grup są dioksyny, stanowi istotny problem ekologiczny i zdrowotny. Polichlorowane dibenzodioksyny (PCDD), okre...
Sklerostyna i przewlekła choroba nerek
Przewlekła choroba nerek (PChN) prowadzi do zaburzeń mineralnych i kostnych, zwiększając częstość złamań, powikłań sercowo-naczyniowych i śmiertelność. Szlak sygnałowy Wnt/β-katenina odgrywa istotną rolę w rozwoju oraz p...